Clinical Trials Browser

Completed × INDUSTRY × Breast × Clear all

Breast Neoplasms

NCT05461430 2026-04-13

TraveraRTGx

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Anus Neoplasms, Appendiceal Neoplasms, Ascites, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Stomach Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Small Cell, Carcinoma, Pancreatic Ductal, Gastrointestinal Stromal Tumors

Clinical Trials

mBC

TraveraRTGx

A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Evaluation of Safety and Performance of Intraoperative Detection of Light Signals During Electrosurgical Breast Cancer Resection

A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

PROSPERITY

ROTOR

Combination Study of SV-BR-1-GM With Retifanlimab

HER2CLIMB-04

SUMIT-ELA

Conventional Therapy vs. Telerehabilitation With TRAK in Patients Undergoing Axillary Lymph Node Removal

BBBD

Study of DF1001 in Patients With Advanced Solid Tumors

EMBLEDDA-MMG

MK-4700-001

TNBC-MERIT

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

KEYLYNK-009

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

SPEAR

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

OlympiAD

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

ProHer

FORTITUDE-301

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

RIBANNA

RESONATE

Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer

ZGMBC

A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants

CARE-MMG-MRMC

BYLieve

BCARE

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

CONFIGURE